Molecules that were previously extremely difficult to synthesize suddenly become accessible.
For over a century, chemists have built molecules the way architects build structures — from the ground up, layer by layer. A team at the University of Vienna has now proposed a different metaphor: editing. Their 'Alkyl Swap' technique allows researchers to reach into an existing molecule and change a single, precise location without dismantling what surrounds it, offering a quieter but potentially transformative shift in how humanity designs the compounds that sustain and heal life.
- Modifying secondary N-methylamines — nitrogen structures found in nearly every effective drug — has long forced chemists into exhausting, multi-step rebuilds or fragile reactions that collapse in the presence of water.
- The University of Vienna team's 'Alkyl Swap' method cuts through that complexity, using common alkenes under conditions so forgiving the researchers half-jokingly call it 'bathtub chemistry.'
- The technique was tested against some of the most widely prescribed pharmaceuticals in the world — fluoxetine, sertraline, citalopram — successfully modifying them in single reaction steps that would normally take weeks.
- Drug discovery depends on synthesizing hundreds of molecular variants to find the right one; Alkyl Swap could compress that search dramatically, unlocking compounds that no existing method could previously reach.
- Beyond its practical applications, the work signals a philosophical shift — from molecular construction to molecular editing — offering chemistry a new grammar for thinking about what is possible.
For more than a century, chemists have built complex molecules the way a builder constructs a house: methodically, from simple ingredients upward, bond by bond. A team at the University of Vienna, led by Nuno Maulide, is now asking whether the future of chemistry looks less like construction and more like editing.
At the center of the question are amines — nitrogen-containing compounds that appear throughout living systems, in proteins, neurotransmitters, and nearly every drug that works. Selectively modifying secondary N-methylamines, a class of amine common in pharmaceuticals, has long been a stubborn problem. Changing them typically meant dismantling the entire molecule and rebuilding it from scratch, requiring either elaborate multi-step syntheses or sensitive metal catalysts that demanded water-free, tightly controlled conditions.
The team's answer is a technique they call 'Alkyl Swap.' Using simple, stable alkenes — common hydrocarbon compounds — it replaces the methyl group on an amine with far more complex molecular fragments, at a single precise location, without disturbing anything else. Co-author Daniel Kaiser describes it plainly as molecular text correction.
What makes the method striking is not only the concept but the conditions. The team calls it 'bathtub chemistry' — a half-joking acknowledgment that the reaction is so robust it could, in principle, be performed in a heated bathtub. Where most comparable methods demand strict exclusion of water and oxygen, this one simply works.
To test its reach, the researchers applied Alkyl Swap to derivatives of fluoxetine, duloxetine, sertraline, atomoxetine, and citalopram — drugs taken by millions — synthesizing several in a single reaction step. Co-author Giulia Iannelli notes the method can functionalize complex amines that no other known technique could touch.
The implications extend into the economics of drug discovery, where chemists must synthesize hundreds of molecular variants to find the right balance of efficacy and safety. Alkyl Swap could compress that timeline, dissolve bottlenecks in late-stage drug modification, and open access to molecular territory that was previously unreachable. More quietly, it represents a new way of thinking — a shift in logic, a new grammar for what chemistry can do.
For more than a century, chemists have approached molecular synthesis the way a builder approaches a house: methodically, piece by piece, foundation to roof. You start with simple ingredients and construct upward, bond by bond, atom by atom, until you have the complex molecule you need. But what if the future of chemistry looked less like construction and more like editing—finding the exact spot in an existing molecule that needs to change, and changing only that?
Amines are the reason this question matters. They are the nitrogen-containing compounds that show up everywhere in living systems: in proteins, in neurotransmitters, in nearly every drug that works. Because organisms have evolved to recognize and interact with amines so readily, modifying them—creating new versions that retain their essential character while gaining new properties—has become central to modern drug discovery. Yet for decades, chemists faced a stubborn problem: how to selectively modify secondary N-methylamines, compounds where a nitrogen atom carries a methyl group. These structures are ubiquitous in pharmaceuticals, but changing them usually meant dismantling the entire molecule and rebuilding it from scratch, a process that demanded either elaborate multi-step syntheses or temperamental metal catalysts that required pristine, water-free laboratory conditions.
Researchers at the University of Vienna, led by Nuno Maulide, have developed a method that sidesteps this entire paradigm. Instead of rebuilding, they edit. The technique, which they call "Alkyl Swap," uses simple alkenes—common hydrocarbon compounds—to directly replace the methyl group on an amine with far more complex molecular fragments. Daniel Kaiser, one of the study's authors, describes the appeal plainly: you can modify even highly intricate molecules at a single, precise location without disturbing anything else. It is molecular text correction.
What makes the breakthrough genuinely remarkable is not just the concept but the conditions under which it works. Most modern amine-modification methods demand strict control: no water, no oxygen, specialized photocatalysts, reagents that must be handled with care. Maulide's team calls their approach "bathtub chemistry"—a half-joking reference to the fact that the reaction is so robust and forgiving that, in theory, you could perform it in a heated bathtub. Of course, they still recommend a proper laboratory. But the point stands: this is chemistry stripped of pretense, chemistry that works under conditions so simple and mild that it opens doors previously locked.
To test the method's reach, the team applied it to molecules with real pharmaceutical weight. They modified derivatives of fluoxetine, duloxetine, sertraline, atomoxetine, and citalopram—drugs that millions of people take. They synthesized several commercially important medications in a single reaction step, a feat that would normally require weeks or months of careful synthesis. Giulia Iannelli, a co-author and former postdoctoral researcher in the group, notes that the method can functionalize complex amines that no other known technique could touch. This is not incremental improvement; this is access to territory that was previously unreachable.
The implications ripple outward. In modern drug research, chemists routinely need to synthesize hundreds of molecular variants to find the one with the right balance of efficacy and safety. Alkyl Swap could compress that timeline dramatically. The method has already proven useful for late-stage modification of complex drug molecules, for attaching drugs to peptides, and for rapidly generating libraries of medically relevant compounds. Each of these applications represents a bottleneck in current drug development that this technique could help dissolve.
But perhaps the deepest significance lies in what the work represents philosophically. Classical amine synthesis relies on aldehydes and reducing agents—a particular way of thinking about how molecules should be built. Alkyl Swap uses simple, stable, readily available alkenes instead. It is a shift in logic, a new grammar for molecular construction. Maulide emphasizes this: what excites the team most is not the specific reaction but the mode of thinking it enables. Molecules that were previously extremely difficult to synthesize suddenly become accessible. On paper, the setup looks almost trivial—an amine, an alkene, formaldehyde in a vessel—yet it may mark a genuine inflection point in how chemists approach their craft.
Notable Quotes
Amines are everywhere—in proteins, drugs, neurotransmitters. The ability to directly and selectively modify such structures is all the more important.— Uroš Vezonik, PhD student, University of Vienna
The reaction is so simple that, in theory, you could even do it in a bathtub. Of course, we still recommend a lab.— Nuno Maulide, University of Vienna
The Hearth Conversation Another angle on the story
Why does it matter that you can modify amines under simple conditions? Couldn't chemists already do this, just with more difficulty?
The difficulty was the barrier. If a reaction requires water-free conditions and sensitive catalysts, you can only do it in specialized labs with specialized equipment. But if it works in a bathtub—well, not literally, but under conditions that simple—suddenly hundreds of research groups can access it. The bottleneck opens.
And the "editing" framing—is that just marketing, or is there something genuinely different about how this works?
It's genuinely different. Traditional synthesis is additive: you build the molecule you want from scratch. This method is subtractive and substitutive: you take a molecule that already exists, find the part that needs to change, and swap it out. You're not rebuilding; you're revising.
What happens to all the drug variants that companies currently synthesize the old way? Does this method make those approaches obsolete?
Not overnight. But for new drug candidates, especially those where you need to test hundreds of variants quickly, this becomes the obvious choice. The old methods don't disappear, but they become less competitive for certain problems.
You mentioned it works on fluoxetine, sertraline—drugs people are already taking. Could this lead to new versions of existing drugs?
Absolutely. You could take a drug that works but has side effects, modify it in ways that were previously impossible, and potentially create a better version. That's the late-stage modification application. It's not inventing new drugs from nothing; it's improving drugs that already exist.
Does the simplicity of the conditions mean it's also cheaper to do?
Almost certainly. You're not buying expensive catalysts or maintaining elaborate equipment. You're using simple alkenes and mild heat. That's a cost advantage on top of the speed advantage.